Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Broncus Holding's ROE % for the quarter that ended in Jun. 2026 was -11.15%. Broncus Holding's PB Ratio for the quarter that ended in Jun. 2026 was 0.26.
Broncus Holding's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -42.88%.
Broncus Holding ROE % Adjusted to Book Value Related Terms
Broncus Holding ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Broncus Holding's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding ROE % Adjusted to Book Value Chart
HKSE:02216 vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Broncus Holding's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Broncus Holding's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -42.88% mean?
Broncus Holding (HKSE:02216) has a ROE % Adjusted to Book Value of -42.88% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Broncus Holding and its competitors.
Is Broncus Holding's ROE % Adjusted to Book Value too high?
Broncus Holding's current ROE % Adjusted to Book Value is -42.88%. Overall, Broncus Holding has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's ROE % Adjusted to Book Value compare to ABT and SYK?
Broncus Holding's ROE % Adjusted to Book Value of -42.88% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Broncus Holding and its competitors. Broncus Holding's current ROE % Adjusted to Book Value is -42.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Based on GuruFocus' analysis, Broncus Holding (HKSE:02216) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.66 — trading 336.7% above its estimated fair value. The current ROE % Adjusted to Book Value is -42.88%. Broncus Holding's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Broncus Holding (HKSE:02216), the current ROE % Adjusted to Book Value is -42.88% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Broncus Holding (HKSE:02216) Overvalued in 2026?
Based on GuruFocus' analysis, Broncus Holding stock appears to be overvalued.
The current stock price of HK$0.66 is trading 336.7% above its estimated GF Value™ of HK$0.15.
GuruFocus considers Broncus Holding to be Significantly Overvalued.
Key valuation signals for HKSE:02216:
ROE % Adjusted to Book Value: -42.88%
GF Value™: HK$0.15 vs. price of HK$0.66 (336.7% above fair value)
No single metric tells the full story. See the HKSE:02216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
43GF Score
Get the complete analysis for HKSE:02216
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02216 has been successfully added to your 
